RegeneRx (RGN) Reports Phase II Pressure Ulcer Trial Results
More News related to RGN
- REGENERX (RGN) Reports Study Data on Tb4 Drug Candidates
- Promising Clinical Data with RegeneRx's Tb4 Drug Candidates Presented on Second Day of Thymosin Meeting
- Scientists Report Impressive Research Results with Tb4 on First Day of Thymosin Meeting
- Unusual 11 Mid-Day Movers 9/30: HOKU, ICCC, VSR, DSCO Higher; CIT, RGN, ICON, HX Lower
- Morning Movers 9/30: HOKU, ICCC, VSR, CFW, DSCO Higher; CIT, HX, RGN, ICON, APAB, RMTI Lower
More News related to Corporate News
- Citigroup (C) Kelly Making Comments At Banking Conference: "Balance Sheet is Very Liquid"
- Rockwell Collins (COL) Awarded $450M U.S. Navy Contract for ARC-210 Radios
- Alvarion (ALVR) Selected by Adam Internet to Deploy WiMAX Network in Adelaide, Australia
- AEterna Zentaris (AEZS) Reports That Perifosine Partner Keryx Biopharma (KERX) Will Prersent Data from Phase 1/2 at 51st ASH Meeting
- Geron Corp. (GERN) Reports that hESC-Derived Oligodendrocyte Progenitor Cells Reduced Cervical Spinal Cord Injury
REGENERX BIOPHARMACEUTICALS, INC. (AMEX: RGN) announced the outcome of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with chronic pressure ulcers. RGN-137 is a topical gel formulation of thymosin beta 4 peptide (Tβ4). The drug candidate was found to be safe and well-tolerated at all three dose levels, with no drug-related serious adverse events, which was the primary objective of the study. Regarding the secondary objective of the study, there were no statistically significant differences observed for complete wound healing or the rate of wound healing between the placebo group and any of the three RGN-137 dose levels. The mid-dose level of RGN-137 was observed to offer more rapid initiation of wound healing when compared to placebo, although this improvement was not statistically significant.
RegeneRx is focused on the discovery and development of novel peptides to accelerate tissue and organ repair.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
